Back to Webinars

14 October 2024

Clinical Leader Solutions Expo: Early-Phase Oncology Trials (CRO)

Clinical Leader Solutions Expo: Early-Phase Oncology Trials (CRO)

Driving Innovation in Cancer Research: Clinical Leader Solutions Expo Highlights Expertise in Early-Phase Oncology Trials.

Oncology has been and continues to be the leading priority in global drug development. 44% of all Phase I-III trials, current and planned, are tackling oncology. But as the push to combat cancer evolves, so too has the drug development arena. In the last decade, small and emerging biopharma has surged to the forefront of oncology development, comprising 70% of 2023 trial starts according to IQVIA Institute. With young, innovative, funding-conscious companies leading the charge, experienced trial partners are pivotal to commercial and patient success.

The Clinical Leader Solutions Expo: Early Phase Oncology CROs brings an array of industry leaders and niche experts from CROs adept in guiding small and emerging biopharma through these complex trials. Designed with input from biotech teams, this event goes beyond basic pitches to highlight the key differentiators of each presenting partner in an interactive forum built for teams just starting to explore CRO services, to those who are ready for conversations.

Related Webinars

The Phase 2 Endpoint Dilemma: Bridging Subjective Scales and Objective Measures in Neurodegenerative Trials

11 March 2026

The Phase 2 Endpoint Dilemma: Bridging Subjective Scales and Objective Measures in Neurodegenerative Trials

Phase 2 neurodegenerative trials are increasingly challenged by slow disease trajectories, heterogeneous patient populations, and blunt legacy endpoints that struggle to detect treatment-related change over typical study durations.

Read more
Unlocking Global Oncology Success: The Strategic Advantage of Australia & Asia for U.S. Biotechs

27 June 2025

Unlocking Global Oncology Success: The Strategic Advantage of Australia & Asia for U.S. Biotechs

This expert panel will explore how Australia, Taiwan, and South Korea provide a strategic advantage in conducting early, mid, and late-phase oncology trials, offering speed, cost efficiency, and global scalability.

Read more
Avance Clinical Clinical Leader Solutions Expo May 2025: CRO Services – Oncology

21 May 2025

Avance Clinical Clinical Leader Solutions Expo May 2025: CRO Services – Oncology

This presentation outlines the key success factors driving high-impact oncology drug development, with a focus on translating innovative science into clinically and commercially meaningful outcomes.

Read more
Early-Phase Oncology: Advantages in Australia & USA

6 August 2024

Early-Phase Oncology: Advantages in Australia & USA

Oncology has been and continues to be the leading priority in global drug development. 44% of all Phase I-III trials, current and planned, are tackling oncology. But as the push to combat cancer evolves, so too has the drug development arena. In the last decade, small and emerging biopharma has surged to the forefront of oncology development, comprising 70% of 2023 trial starts according to IQVIA Institute. With young, innovative, funding-conscious companies leading the charge, experienced trial partners are pivotal to commercial and patient success.

Read more
Psychedelics in Focus: Clinical Trials, Transformations and Regulations

21 May 2024

Psychedelics in Focus: Clinical Trials, Transformations and Regulations

Join us for an informative webinar as we delve into the world of psychedelic trials and the evolving regulatory landscape surrounding these transformative therapies.

Read more